Nova Biomedical Announces BioProfile® FLEX 2 Basic Comprehensive Cell Culture Analyzers


FOR IMMEDIATE RELEASE: June 6, 2024
Contact: Matthew McRae 
(781) 647-3700 ext. 1446
mmcrae@novabio.com

Waltham, MA - Nova Biomedical announces BioProfile FLEX2 Basic, the next addition to the company’s BioProfile line of cell culture chemistry analyzers. BioProfile FLEX2 Basic analyzers incorporate Nova’s maintenance-free MicroSensor™ Card technology that eliminates sensor maintenance and maximizes workflow efficiency. BioProfile FLEX2’s focused test menus are ideal for cell therapy, gene therapy, vaccine development, and alternative foods applications.

BioProfile FLEX2 Basic is available in 3 models—FLEX2 Basic A, B, and C. The Basic A model provides a full 11-test menu of gases, electrolytes, and metabolites with automatic dilutions and extended test ranges. The full menu includes pH, pCO2, pO2, Gluc, Lac, Na+, K+, Ca++, Gln, Glu, NH4+. The Basic B, and C models have the same 265µL sample volume and 2-minute analysis time, but with standard ranges and more focused test menus where the full analyzer capabilities are not needed.

BioProfile FLEX2 Basic’s maintenance-free technology comprises two credit card-sized MicroSensor cards that are replaceable in seconds. FLEX2 reagent cartridges and MicroSensor cards incorporate RFID technology for simple, snap-in replacement with no additional user input. BioProfile FLEX2’s reagent cartridges combined with maintenance-free MicroSensor Card technology reduce maintenance to just minutes per week.

“We at Nova Biomedical are extremely excited to launch the next addition to the BioProfile line of cell culture analyzers with BioProfile FLEX2 Basic. FLEX2 Basic allows scientists to begin to optimize their cell culture analysis processes with meaningful data for cell therapy/gene therapy, vaccine development, and alternative foods research,” said Matthew McRae, Biotechnology Sales Product Line Manager at Nova. “We take pride in customer-focused designs that provide our users with the most flexible analyzer options and best workflows of any analyzer line in the industry.”

Based on customer needs in these emerging markets, Nova Biomedical created the FLEX2 Basic A, B, and C analyzers to address their unique requirements. As their needs expand, these customers can take advantage of the power and flexibility of our 16-test FLEX2 analyzer that adds osmolality and cell density/cell viability analysis to the chemistry and gas functions. BioProfile FLEX2 also offers automation in direct sampling from ambr® microbioreactors and standard bioreactors from table-top to production size. Designed for small volume, early-stage cell culture development through GMP manufacturing, BioProfile FLEX2 and FLEX2 Basic provide 21 CFR Part 11 compliance, OPC connectivity, full networking functionality, and support with all validation needs. 

 

 

About Nova Biomedical
Incorporated in 1976 and based in Waltham, MA, Nova Biomedical is a world leader in the development and manufacturing of whole blood, point-of-care and critical care analyzers, as well as instruments for cell culture monitoring in the biotechnology market. Nova uses biosensor technology in products ranging from handheld meters for glucose self- and point-of-care testing to critical care whole blood analyzers designed for stat measurement of over 24 analytes. Nova’s BioProfile line has pioneered comprehensive cell culture testing, providing over 20 critical cell culture tests for a broad range of cell culture applications. Nova employs over 1,500 people worldwide and has wholly owned subsidiaries located in Australia, Benelux, Brazil, Canada France, Germany, Great Britain, Italy, Japan, Spain, and Switzerland. Certified by the International Organization for Standardization, Nova has manufacturing operations located in the U.S. and Taiwan.
www.novabiomedical.com